SM 20220Alternative Names: SM-20220
Latest Information Update: 08 Feb 2008
At a glance
- Originator Dainippon Sumitomo Pharma
- Class Anti-ischaemics; Neuroprotectants
- Mechanism of Action Sodium hydrogen antiporter inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuroprotection